Skip Navigation

Cardiovascular Research 2004 64(3):412-420; doi:10.1016/j.cardiores.2004.09.014
© 2004 by European Society of Cardiology
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Azuma, R. W.
Right arrow Articles by Isobe, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Azuma, R. W.
Right arrow Articles by Isobe, M.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Copyright © 2004, European Society of Cardiology

HMG-CoA reductase inhibitor attenuates experimental autoimmune myocarditis through inhibition of T cell activation

Ryoko Wakizono Azuma, Jun-ichi Suzuki, Masahito Ogawa, Hideki Futamatsu, Noritaka Koga, Yasuyuki Onai, Hisanori Kosuge and Mitsuaki Isobe*

Department of Cardiovascular Medicine, Tokyo Medical and Dental University, 1-5-45 Yushima, Bunkyo-ku, Tokyo 113-8519, Japan

* Corresponding author. Tel.: +81 3 5803 5951; fax: +81 3 5803 0238. Email address: isobemi.cvm{at}tmd.ac.jp

Objective: This study tested the hypothesis that 3-hydroxy-3-methyl-glutaryl coenzyme A (HMG-CoA) reductase inhibitor affects T cell-mediated autoimmunity through inhibition of nuclear factor-{kappa}B (NF{kappa}B) and reduces the severity of experimental autoimmune myocarditis (EAM).

Methods: EAM was induced in Lewis rats by immunization with myosin. High-dose or low-dose fluvastatin or vehicle was administered orally for 3 weeks to rats with EAM.

Results: Fluvastatin reduced the pathophysiological severity of myocarditis. Fluvastatin inhibited expression of NF{kappa}B in the nuclei of myocardium in EAM. Fluvastatin reduced production of Th1-type cytokines, including interferon (IFN)-{gamma} and interleukin (IL)-2, and inhibited expression of inflammatory cytokine mRNAs in the myocardium. Infiltration of CD4-positive T cells into the myocardium and T cell proliferative responses were suppressed by fluvastatin. Plasma lipid levels did not differ between the groups.

Conclusions: Fluvastatin ameliorates EAM by inhibiting T cell responses and suppressing Th1-type and inflammatory cytokines via inactivation of nuclear factor-{kappa}B, and this activity is independent of cholesterol reduction.

KEYWORDS HMG-CoA reductase inhibitor; Myocarditis; Nuclear factor-{kappa}B; Cytokine; T cell response; Inflammation; Immunology

Time for primary review 17 days


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 NeurologyHome page
G. Birnbaum, B. Cree, I. Altafullah, M. Zinser, and A. T. Reder
Combining beta interferon and atorvastatin may increase disease activity in multiple sclerosis
Neurology, October 28, 2008; 71(18): 1390 - 1395.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.